Taysha Gene Therapies Inc
TSHA2.710USD
+0.080+3.04%
收盤 08/04, 16:00（美東）報價延遲15分鐘
555.70M總市值
虧損本益比TTM
關於 Taysha Gene Therapies Inc 公司
Taysha Gene Therapies Inc 是一家臨牀階段的生物技術公司，專注於推進腺相關病毒 (AAV) 基因療法，用於治療嚴重的中樞神經系統單基因疾病。該公司的主要臨牀項目 TSHA-102 正在開發中，用於治療罕見的神經發育障礙雷特綜合徵。該公司正在 REVEALPhase I/II 青少年和成人臨牀試驗中評估 TSHA-102，這是一項首次在人體中進行的開放標籤、隨機、劑量遞增和劑量擴展的多中心研究，評估 TSHA-102 對 12 歲及以上患有雷特綜合徵的女性患者的安全性和初步療效。該公司已獲得臨牀階段鞘內給藥 AAV9 基因治療項目 TSHA-120 的全球權利，用於治療巨軸突神經病變 (GAN)。該公司的TSHA-120用於治療GAN，獲得了歐盟委員會的孤兒藥稱號。
公司簡介
公司代碼TSHA
公司名稱Taysha Gene Therapies Inc
上市日期Sep 24, 2020
CEOMr. Sean Patrick Nolan
員工數量73
證券類型Ordinary Share
年結日Sep 24
公司地址3000 Pegasus Park Drive
城市DALLAS
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編75247
電話12146120000
網址https://tayshagtx.com/
公司代碼TSHA
上市日期Sep 24, 2020
CEOMr. Sean Patrick Nolan
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Sean Stalfort
Mr. Sean Stalfort
Independent Director
Independent Director
2.04M
+2.86%
Mr. Kamran Alam
Mr. Kamran Alam
Chief Financial Officer
Chief Financial Officer
362.05K
-38.56%
Mr. Sean Patrick Nolan
Mr. Sean Patrick Nolan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
297.34K
-66.73%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
President, Head of Research and Development, Director
President, Head of Research and Development, Director
250.13K
-30.27%
Dr. Laura Sepp-Lorenzino, Ph.D.
Dr. Laura Sepp-Lorenzino, Ph.D.
Independent Director
Independent Director
105.84K
+115.04%
Dr. Alison Long
Dr. Alison Long
Independent Director
Independent Director
--
--
Mr. Phillip B. (Phil) Donenberg
Mr. Phillip B. (Phil) Donenberg
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Sean Stalfort
Mr. Sean Stalfort
Independent Director
Independent Director
2.04M
+2.86%
Mr. Kamran Alam
Mr. Kamran Alam
Chief Financial Officer
Chief Financial Officer
362.05K
-38.56%
Mr. Sean Patrick Nolan
Mr. Sean Patrick Nolan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
297.34K
-66.73%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
President, Head of Research and Development, Director
President, Head of Research and Development, Director
250.13K
-30.27%
Dr. Laura Sepp-Lorenzino, Ph.D.
Dr. Laura Sepp-Lorenzino, Ph.D.
Independent Director
Independent Director
105.84K
+115.04%
Dr. Alison Long
Dr. Alison Long
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月28日 週一
更新時間: 7月28日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Manning (Paul B.)
10.16%
Avoro Capital Advisors LLC
7.94%
RTW Investments L.P.
7.46%
Fidelity Management & Research Company LLC
6.21%
Morgan Stanley & Co. LLC
5.81%
Other
62.42%
持股股東
持股股東
佔比
Manning (Paul B.)
10.16%
Avoro Capital Advisors LLC
7.94%
RTW Investments L.P.
7.46%
Fidelity Management & Research Company LLC
6.21%
Morgan Stanley & Co. LLC
5.81%
Other
62.42%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
22.38%
Investment Advisor
21.43%
Hedge Fund
11.79%
Individual Investor
11.50%
Research Firm
6.38%
Venture Capital
4.65%
Corporation
0.61%
Sovereign Wealth Fund
0.58%
Bank and Trust
0.10%
Other
20.58%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
272
200.20M
79.47%
-19.12M
2025Q1
280
208.55M
85.47%
-19.89M
2024Q4
274
206.61M
100.79%
-12.49M
2024Q3
266
194.14M
94.73%
-23.74M
2024Q2
250
196.13M
97.09%
+4.27M
2024Q1
251
185.84M
99.33%
-1.52M
2023Q4
229
175.44M
93.86%
-4.17M
2023Q3
220
173.81M
93.01%
+41.64M
2023Q2
198
39.38M
61.40%
-9.23M
2023Q1
206
43.11M
72.56%
+244.20K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Manning (Paul B.)
25.60M
10.16%
+750.00K
+3.02%
May 30, 2025
Avoro Capital Advisors LLC
20.00M
7.94%
--
--
Mar 31, 2025
RTW Investments L.P.
18.79M
7.46%
+10.12M
+116.63%
Mar 31, 2025
Fidelity Management & Research Company LLC
15.63M
6.21%
-733.71K
-4.48%
Mar 31, 2025
Morgan Stanley & Co. LLC
14.64M
5.81%
-813.81K
-5.27%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
12.44M
4.94%
-91.46K
-0.73%
Mar 31, 2025
RA Capital Management, LP
10.87M
4.32%
--
--
Mar 31, 2025
Octagon Capital Advisors LP
10.70M
4.25%
+250.00K
+2.39%
Mar 31, 2025
The Vanguard Group, Inc.
8.77M
3.48%
-135.84K
-1.53%
Mar 31, 2025
Invus Public Equities Advisors, LLC
6.51M
2.59%
-87.74K
-1.33%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
1.21%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
Texas Capital Texas Small Cap Equity Index ETF
0.41%
iShares Micro-Cap ETF
0.09%
SPDR S&P Biotech ETF
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Goldman Sachs Innovate Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
Direxion Daily S&P Biotech Bull 3X Shares
0.04%
查看更多
iShares Neuroscience and Healthcare ETF
佔比1.21%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.78%
Texas Capital Texas Small Cap Equity Index ETF
佔比0.41%
iShares Micro-Cap ETF
佔比0.09%
SPDR S&P Biotech ETF
佔比0.07%
Invesco Nasdaq Biotechnology ETF
佔比0.07%
ProShares Ultra Nasdaq Biotechnology
佔比0.07%
Goldman Sachs Innovate Equity ETF
佔比0.04%
iShares Biotechnology ETF
佔比0.04%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.04%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
